Clinical Trials
20 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT04314401 2026-05-13
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Active not recruiting
NCT04354246 2026-05-12
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Phase 1 Completed
NCT05645510 2026-05-11
LONGEVITI
University of Alberta
Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT02333604 2026-04-23
CER
Cancer Support Community, Research and Training Institute, Philadelphia
Recruiting
NCT07290309 2026-03-31
SURGE
Colorado State University
Phase NA Recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT05974150 2026-02-23
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Carevive Systems, Inc.
Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT07403630 2026-02-17
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
Phase NA Recruiting
NCT02407509 2026-01-29
RAF/MEK
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT03702309 2025-11-26
LIBERATE
University Health Network, Toronto
Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04000880 2025-06-12
AMPLIFY
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT05567601 2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1 Completed